ReviewCureus2026
Metabolic Syndrome in Focus: Emerging Causes, New Diagnostic Approaches and Criteria, and Long-Term Health Consequences.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a complex cluster of metabolic abnormalities, including central obesity, hypertension, dyslipidemia, insulin resistance, and impaired glucose metabolism. Growing evidence indicates that MetS is not only a major risk factor for cardiovascular disease but is also strongly associated with the development and progression of various malignancies. Owing to shared pathophysiological mechanisms, MetS represents an important link between oncologic and cardiovascular diseases. This narrative review aims to provide an integrative assessment of the role of MetS in oncologic and cardiovascular outcomes, with particular emphasis on emerging pathophysiological mechanisms and evolving diagnostic criteria. By synthesizing current evidence, this review addresses existing gaps in the literature regarding the interconnected impact of MetS on long-term health outcomes. A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science, including epidemiological studies, meta-analyses, and clinical studies published between 2000 and 2025 that evaluated associations between MetS, cancer, and cardiovascular disease. Current evidence suggests that MetS significantly increases the risk of both malignancies and cardiovascular disorders. Central mechanisms include chronic low-grade inflammation, insulin resistance with activation of insulin-like growth factor (IGF) signaling pathways, dysregulated lipid metabolism, and endothelial dysfunction. Lifestyle modifications, particularly regular physical activity and antioxidant-rich diets, as well as metabolically targeted pharmacological strategies, may reduce disease incidence and progression. In conclusion, MetS represents a critical, modifiable risk factor linking cancer and cardiovascular disease. Early identification and comprehensive management of MetS may play a pivotal role in improving long-term clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.